Table 7 Comparison of the performance of referable DR grading from different systems in clinic settings
IDx-DR (DR) | EyeArt (DR) | SELENA+ (DR) | Offline AI System* (DR) | VoxelCloud Retina (DR) | RAIDS (DR, AMD, and Glaucoma) | TeleEye MD (DR, AMD, and Glaucoma) |
|---|---|---|---|---|---|---|
Validated on 900 patients SE: 87.2%; SP: 90.7% IDx-DR 2.0 Validated on 1415 patients in the Hoorn Diabetes Care System SE: 91% SP: 84% (Using EURODIAB criteria) | EyeArt v2.1 Validated on 30,405 patients in the English Diabetic Eye Screening Programme in the UK SE: 95.7% SP: 54.0% Validated on 893 patients SE: 95.5% SP: 85.3% | Validated on 1574 patients in a mobile screening program in Zambia SE: 92.3% SP: 89.0% Validated on 69 patients in Australia SE: 96.9% SP: 87.7% | Validated on 236 participants in Australia SE: 96.9% SP: 87.7% | Validated on 15,805 patients at 155 diabetes centres in China SE: 83.3% SP: 92.5% | Validated on 110,784 participants from 65 healthcare centers in China DR SE: 83.7% SP: 98.6% AMD SE: 88.1% SP: 97.6% Referral possible glaucoma SE: 81.3% SP: 95.0% | Validated on 231 Patient in this study DR SE: 100.0% SP: 80.1% AMD SE: 90.9% SP: 78.8% Referral possible glaucoma SE: 93.2% SP: 76.8% |